Decheng Capital Management Iii (Cayman), LLC Aadi Bioscience, Inc. Call Options Transaction History
Decheng Capital Management Iii (Cayman), LLC
- $181 Million
- Q3 2023
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AADI
# of Institutions
65Shares Held
12MCall Options Held
9.4KPut Options Held
2.5K-
Avoro Capital Advisors LLC New York, NY2.85MShares$5.67 Million0.06% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$3.68 Million2.91% of portfolio
-
Satter Management Co., L.P.1.63MShares$3.25 Million4.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$1.52 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA510KShares$1.01 Million0.11% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $41.8M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...